Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Add HCMI Cohort #71

Open
ayan-b opened this issue Jul 3, 2019 · 3 comments
Open

Add HCMI Cohort #71

ayan-b opened this issue Jul 3, 2019 · 3 comments
Assignees

Comments

@ayan-b
Copy link
Collaborator

ayan-b commented Jul 3, 2019

No description provided.

@ayan-b ayan-b self-assigned this Jul 3, 2019
@maryjgoldman
Copy link

Please hold off on this until I determine if it's worth getting this data in. I will update here when it is

@maryjgoldman
Copy link

maryjgoldman commented Jul 3, 2019

Tumor (6 are primary, 1 met) - DNA and RNA
organoid - DNA and RNA
blood derived normal - only DNA
-> Only RNA is open
-> Does have clinical and biospecimen XML files

Have 7 samples now with sequencing. Have models for 28 total but no sequencing data yet, aiming to have 1k samples by the end of the project
Primary Site: Brain, Colon, Rectum

Notes from https://ocg.cancer.gov/programs/hcmi/research
The tumor-derived models, normal tissue, and parent tumor generated from the NCI-supported CMDCs are sequenced. The sequencing information, as well as patients’ clinical data, will be available to researchers.

Background
Many of the cancer lines that are commonly used in cancer research were established decades ago. These cell lines have been useful for in vitro experiments to study cancer biology, biochemistry, and drug targets. However, drawing conclusions about how in vitro observations may relate to clinical biology is challenging because cancer cell lines:

  • lack the cellular complexity and architecture of human tumors, which introduces possibility that genetic drift may have occurred after the cell line was established.
    are not associated with clinical information from the patient.
  • genomic relatedness to the parent tumor is unknown, and molecular characterization including assessment of genomes and transcriptomes of these cell lines, until recently, were mostly unavailable.
  • from diverse racial and ethnic groups and rare cancers are seldom represented in currently available cell lines.

HCMI addresses the deficiencies in current models by collecting patients’ clinical data and assessing, as much as possible, the genomes and transcriptomes of the parent tumor, case-matched normal tissue, and the resulting next-generation cancer model. The information collected will be made available to the end-user.

@maryjgoldman
Copy link

Link to look at the organoids, etc they have already: https://hcmi-searchable-catalog.nci.nih.gov/

@maryjgoldman maryjgoldman assigned maryjgoldman and unassigned ayan-b Jul 3, 2019
Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment
Labels
None yet
Projects
None yet
Development

No branches or pull requests

2 participants